66f35aa5
2021-10-04
Better be cautious
Merck Says Completes Enrolment Of Evobrutinib Phase III Clinical Trials
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
1
5
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":820077600,"tweetId":"820077600","gmtCreate":1633334091941,"gmtModify":1633334092226,"author":{"id":3585027190392565,"idStr":"3585027190392565","authorId":3585027190392565,"authorIdStr":"3585027190392565","name":"66f35aa5","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":13,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Better be cautious</p></body></html>","htmlText":"<html><head></head><body><p>Better be cautious</p></body></html>","text":"Better be cautious","highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/820077600","repostId":2172998129,"repostType":4,"repost":{"id":"2172998129","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"T-Reuters","id":"1086160438","head_image":"https://static.tigerbbs.com/a113a995fbbc262262d15a5ce37e7bc5"},"pubTimestamp":1633332318,"share":"https://www.laohu8.com/m/news/2172998129?lang=&edition=full","pubTime":"2021-10-04 15:25","market":"us","language":"en","title":"Merck Says Completes Enrolment Of Evobrutinib Phase III Clinical Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2172998129","media":"T-Reuters","summary":"Merck KGaA: Merck Completes Enrolment Of Evobrutinib Phase Iii Clinical Trials Ahead Of Ectrims 2021","content":"<p>Merck KGaA: Merck Completes Enrolment Of Evobrutinib Phase Iii Clinical Trials Ahead Of Ectrims 2021.Investigational Evobrutinib Is The First Bruton’S Tyrosine Kinase (Btk) Inhibitor To Complete Phase Iii Clinical Trial Enrolment In Relapsing Multiple Sclerosis (Rms).Data From Oral Presentations At Ectrims Show Evobrutinib Has A Positive Impact On Important Biomarkers Of Disease Progression.New Independent Data Also Presented Found That Patients Treated With Mavenclad® (Cladribine Tablets) Had Increased Antibody Igg Titer Levels Similar To That Of The General Population After A Complete Course Of An Mrna Covid-19 Vaccine.Further Company Coverage:. (Berlin Speed Desk). </p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Merck Says Completes Enrolment Of Evobrutinib Phase III Clinical Trials</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMerck Says Completes Enrolment Of Evobrutinib Phase III Clinical Trials\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086160438\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a113a995fbbc262262d15a5ce37e7bc5);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">T-Reuters </p>\n<p class=\"h-time\">2021-10-04 15:25</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Merck KGaA: Merck Completes Enrolment Of Evobrutinib Phase Iii Clinical Trials Ahead Of Ectrims 2021.Investigational Evobrutinib Is The First Bruton’S Tyrosine Kinase (Btk) Inhibitor To Complete Phase Iii Clinical Trial Enrolment In Relapsing Multiple Sclerosis (Rms).Data From Oral Presentations At Ectrims Show Evobrutinib Has A Positive Impact On Important Biomarkers Of Disease Progression.New Independent Data Also Presented Found That Patients Treated With Mavenclad® (Cladribine Tablets) Had Increased Antibody Igg Titer Levels Similar To That Of The General Population After A Complete Course Of An Mrna Covid-19 Vaccine.Further Company Coverage:. (Berlin Speed Desk). </p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRK":"默沙东"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2172998129","content_text":"Merck KGaA: Merck Completes Enrolment Of Evobrutinib Phase Iii Clinical Trials Ahead Of Ectrims 2021.Investigational Evobrutinib Is The First Bruton’S Tyrosine Kinase (Btk) Inhibitor To Complete Phase Iii Clinical Trial Enrolment In Relapsing Multiple Sclerosis (Rms).Data From Oral Presentations At Ectrims Show Evobrutinib Has A Positive Impact On Important Biomarkers Of Disease Progression.New Independent Data Also Presented Found That Patients Treated With Mavenclad® (Cladribine Tablets) Had Increased Antibody Igg Titer Levels Similar To That Of The General Population After A Complete Course Of An Mrna Covid-19 Vaccine.Further Company Coverage:. (Berlin Speed Desk).","news_type":1},"isVote":1,"tweetType":1,"viewCount":600,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":16,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/820077600"}
精彩评论